# MIcrovascular dysfuNction In Moderate-severe Psoriasis

> **NCT04271540** · PHASE4 · COMPLETED · sponsor: **Marcelo F. Di Carli, MD, FACC** · enrollment: 36 (actual)

## Conditions studied

- Psoriasis
- Cardiovascular Disease

## Interventions

- **DRUG:** Tildrakizumab

## Key facts

- **NCT ID:** NCT04271540
- **Lead sponsor:** Marcelo F. Di Carli, MD, FACC
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-04
- **Primary completion:** 2024-07-03
- **Final completion:** 2024-07-17
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04271540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04271540, "MIcrovascular dysfuNction In Moderate-severe Psoriasis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04271540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*